Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Dr. Muthu was last associated with Mankind Pharma
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Subscribe To Our Newsletter & Stay Updated